

# Medicines and Healthcare products Regulatory Agency

## MANUFACTURER'S AUTHORISATION

<b>1: Authorisation Number</b>	UK MIA(IMP) 43821
<b>2: Name of authorisation holder</b>	ADAPT IMMUNE LIMITED ADAPT IMMUNE LIMITED, 60 JUBILEE AVENUE, MILTON PARK, MILTON, ABINGDON, OX14 4RX, UNITED KINGDOM
<b>3: Address(es) of manufacturing site(s)</b>	ADAPT IMMUNE LIMITED, MODULE 5, CELL & GENE THERAPY CATAPULT MANUFACTURING CENTRE, GUNNELS WOOD ROAD, STEVENAGE, SG1 2FX, UNITED KINGDOM
<b>4: Legally registered address of authorisation holder</b>	ADAPT IMMUNE LIMITED, 60 JUBILEE AVENUE, MILTON PARK, MILTON, ABINGDON, OX14 4RX, UNITED KINGDOM
<b>5: Scope of authorisation and dosage forms</b>	ANNEX 1 and/ or ANNEX 2
<b>6: Legal Basis of authorisation</b>	Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 [SI 2004/1031]
<b>7: Name of responsible officer of the competent authority of the member state granting the manufacturing authorisation</b>	Confidential
<b>8: Authorisation Date</b>	09/05/2024
<b>9: Annexes attached</b>	Annex 1 and/or Annex 2

### SCOPE OF AUTHORISATION

#### Annex 2

Name and address of the site:

**ADAPT IMMUNE LIMITED**, 60 JUBILEE AVENUE, MILTON PARK, MILTON, ABINGDON, OX14 4RX, UNITED KINGDOM

Human Investigational Medicinal Products
Authorised Operations
IMPORTATION OF MEDICINAL PRODUCTS (according to part 2)
Part 2 - IMPORTATION OF MEDICINAL PRODUCTS [ 2.2 ] <b>Batch certification of imported medicinal products</b> [ 2.2.3 ] Biological medicinal products [ 2.2.3.3 ] Cell therapy products [ 2.2.3.4 ] Gene therapy products

## SCOPE OF AUTHORISATION

### Annex 2

Name and address of the site:

**ADAPT IMMUNE LIMITED**, MODULE 5, CELL & GENE THERAPY CATAPULT MANUFACTURING CENTRE, GUNNELS WOOD ROAD, STEVENAGE, SG1 2FX, UNITED KINGDOM

Human Investigational Medicinal Products
Authorised Operations
MANUFACTURING OPERATIONS (according to part 1)
<b>Part 1 - MANUFACTURING OPERATIONS</b> <b>[ 1.1 ] Sterile Investigational Medicinal Products</b> [ 1.1.1 ] Aseptically prepared (processing operations for the following dosage forms) [ 1.1.1.6 ] Other aseptically prepared products Ex vivo viral vector <b>[ 1.3 ] Biological investigational medicinal products</b> [ 1.3.1 ] Biological medicinal products [ 1.3.1.4 ] Gene therapy products <b>Special Requirements</b> Ex vivo viral vectors <b>[ 1.4 ] Other investigational medicinal products or manufacturing activity</b> [ 1.4.2 ] Sterilisation of active substances/excipients/finished products: [ 1.4.2.1 ] Filtration